Andere talen Resverlogix Corp.

Aandelen

RVX

CA76128M1086

Beurs gesloten - Toronto S.E. Andere beurzen 21:56:26 13-09-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0600 ^CAD	-11,11%		-20,00%	-14,29%

15/08	Resverlogix Corp. Rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2024	CI
15/05	Resverlogix Corp. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024	03/09
Resverlogix : MD&A Q2 2024	15/08
Resverlogix : Financial Statement Q2 2024	15/08
Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	15/08
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension	01/08
Resverlogix : Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension	01/08
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges	16/07
Resverlogix : Annual Meeting of Shareholders - Notice of Meeting and Management Information Circular 2024	10/07
Resverlogix Announces Updated Annual and Special Meeting of Shareholders	28/05
Resverlogix : Financial Statement Q1 2024	15/05
Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges	13/05
Resverlogix Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Resverlogix Announces Change to Its Board of Directors	22/02
Resverlogix Corp. Announces Resignation of Shawn Lu from the Board of Directors	21/02
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits	11/01
Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Resverlogix Corp. Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes	04-10-23
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy	04-10-23
RESVERLOGIX ANNOUNCES A FAVORABLE OUTLOOK BASED ON NEW CARDIOVASCULAR DISEASE TREATMENT GUIDELINES FOR PATIENTS WITH TYPE 2 DIABETES	30-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Resverlogix Corp.

Aandelen

RVX

CA76128M1086

Andere talen

Filters